Please login to the form below
Oxford BioMedica
This page shows the latest Oxford BioMedica news and features for those working in and with pharma, biotech and healthcare.
Oxford Biomedica gets £53m cash injection from Novo venture arm
Cell and gene therapy specialist Oxford Biomedica has been given a £53.5m infusion of cash from Novo Holdings in exchange for a 10% stake in the company. ... John Dawson. “We are delighted that Novo Holdings has become a shareholder in Oxford Biomedica
Latest news
-
Oxford Biomedica taps Microsoft to progress gene therapy delivery tech
Will develop in silico models and novel algorithms. Oxford Biomedica has entered into a two-year research and development partnership with Microsoft to change the way gene therapies are delivered and ... Oxford Biomedica’s lentiviral vectors platform,
-
Blackwood returns as new life sciences minister
Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector
-
Axovant drops last ‘legacy’ drug to focus on gene therapies
licensed rights to a gene therapy for Parkinson’s disease (PD) from UK biotech Oxford BioMedica for $30m upfront.
-
UK life sciences gets some Brexit relief with £1.3bn sector deal
£19m commitment from Oxford BioMedica to expand manufacturing facilities.
-
Digital tech from Autolus and Oxford BioMedica to speed advanced therapies
Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy ... Oxford Biomedica will look to dramatically reduce the
More from news
Approximately 3 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Deal Watch table for October 2014
95. Oxford BioMedica/Novartis. Expansion of collaboration. Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia.
-
Pharma deals during October 2014
First closed in May 2013, Novartis has expanded its collaboration with Oxford BioMedica. ... This is focused on the manufacture and supply, using Oxford's LentiVector gene delivery technology, to express Novartis' chimeric antigen receptor T cell [CAR-T]
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Prior to this, he was non-executive director and then chairman of Oxford BioMedica, a gene-based biopharmaceutical company.
-
Dr Simon Chandler joins Ora as a senior director
Prior to joining Ora, Dr Chandler served as principal of Sci-pHecta Consulting from 2013 and has also held leadership roles at Bausch Lamb, Ista Pharmaceuticals, NightStaRx BioPharmaceuticals and Oxford BioMedica
-
ABPI names first project director for manufacturing
James Christie joins from Oxford BioMedica. The Association of the British Pharmaceutical Industry (ABPI) has named James Christie as its first project director with responsibility for manufacturing. ... Prior to joining ABPI, Christie worked for Oxford
-
Paul Blake joins Oxford BioMedica
John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative ... therapies will be important to Oxford
-
BIA elects six new board members
The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Roche’s Ocrevus boasts positive long-term data in MS
- FDA approves Roche’s Actemra COVID-19 trial
- Leadership change within Bedrock Group
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
